CHAPTER III AUTHORISATION PROCEDURE FOR A SUBSTANTIAL MODIFICATION OF A CLINICAL TRIAL
Article 17.Validation of an application for the authorisation of a substantial modification of an aspect covered by Part I of the assessment report
Article 18.Assessment of a substantial modification of an aspect covered by Part I of the assessment report
Article 19.Decision on the substantial modification of an aspect covered by Part I of the assessment report
Article 20.Validation, assessment and decision regarding a substantial modification of an aspect covered by Part II of the assessment report
Article 21.Substantial modification of aspects covered by Parts I and II of the assessment report
Article 22.Assessment of a substantial modification of aspects covered by Parts I and II of the assessment report — Assessment of the aspects covered by Part II of the assessment report
Article 23.Decision on the substantial modification of aspects covered by Parts I and II of the assessment report
Article 24.Persons assessing the application for a substantial modification
CHAPTER VI START, END, TEMPORARY HALT, AND EARLY TERMINATION OF A CLINICAL TRIAL
Article 36.Notification of the start of a clinical trial and of the end of the recruitment of subjects
Article 37.End of a clinical trial, temporary halt and early termination of a clinical trial and submission of the results
Article 38.Temporary halt or early termination by the sponsor for reasons of subject safety
Article 39.Update of the contents of the summary of results and summary for laypersons
CHAPTER VII SAFETY REPORTING IN THE CONTEXT OF A CLINICAL TRIAL
Article 47.Compliance with the protocol and good clinical practice
Article 49.Suitability of individuals involved in conducting the clinical trial
Article 51.Traceability, storage, return and destruction of investigational medicinal products
Article 53.Other reporting obligations relevant for subject safety
Article 56.Recording, processing, handling and storage of information
CHAPTER XIII SUPERVISION BY MEMBER STATES, UNION INSPECTIONS AND CONTROLS
APPLICATION DOSSIER FOR THE INITIAL APPLICATION
6. The cover letter shall specify the EU trial number and...
8. The cover letter shall indicate where the information listed in...
9. The cover letter shall indicate if the clinical trial is...
10. The cover letter shall indicate if the methodology of the...
11. The cover letter shall indicate the location in the application...
12. In the case of a resubmission, the cover letter shall...
14. The protocol shall describe the objective, design, methodology, statistical considerations,...
16. The protocol shall, when possible, be written in an easily...
18. If a clinical trial is conducted with an active substance...
19. With regard to the notification of adverse events, the protocol...
21. In case the sponsor intends to submit a single safety...
22. Issues regarding labelling and the unblinding of investigational medicinal products...
23. The protocol shall be accompanied by the Charter of the...
24. The protocol shall be accompanied by a synopsis of the...
F. DOCUMENTATION RELATING TO COMPLIANCE WITH GOOD MANUFACTURING PRACTICE (GMP) FOR...
31. As regards documentation relating to GMP compliance, the following shall...
32. No documentation needs to be submitted where the investigational medicinal...
33. If the investigational medicinal product is not authorised, and does...
34. In all other cases, a copy of the authorisation referred...
35. For processes related to investigational medicinal products set out in...
G. INVESTIGATIONAL MEDICINAL PRODUCT DOSSIER (IMPD)
36. The IMPD shall give information on the quality of any...
1.1. Data relating to the investigational medicinal product
Non-clinical pharmacology and toxicology data
41. The IMPD shall also contain summaries of non-clinical pharmacology and...
42. Non-clinical pharmacology and toxicology data shall be submitted in a...
43. The IMPD shall provide a critical analysis of the data,...
44. The IMPD shall contain a statement of the good laboratory...
45. The test material used in toxicity studies shall be representative...
I. SCIENTIFIC ADVICE AND PAEDIATRIC INVESTIGATION PLAN (PIP)
J. CONTENT OF THE LABELLING OF THE INVESTIGATIONAL MEDICINAL PRODUCTS
K. RECRUITMENT ARRANGEMENTS (INFORMATION PER MEMBER STATE CONCERNED)
L. SUBJECT INFORMATION, INFORMED CONSENT FORM AND INFORMED CONSENT PROCEDURE (INFORMATION...
M. SUITABILITY OF THE INVESTIGATOR (INFORMATION PER MEMBER STATE CONCERNED)
N. SUITABILITY OF THE FACILITIES (INFORMATION PER MEMBER STATE CONCERNED)
O. PROOF OF INSURANCE COVER OR INDEMNIFICATION (INFORMATION PER MEMBER STATE...
P. FINANCIAL AND OTHER ARRANGEMENTS (INFORMATION PER MEMBER STATE CONCERNED)
Q. PROOF OF PAYMENT OF FEE (INFORMATION PER MEMBER STATE CONCERNED)...
R. PROOF THAT DATA WILL BE PROCESSED IN COMPLIANCE WITH UNION...
1. REPORTING OF SERIOUS ADVERSE EVENTS BY THE INVESTIGATOR TO THE...
2. REPORTING OF SUSPECTED UNEXPECTED SERIOUS ADVERSE REACTIONS (SUSARS) BY THE...
CONTENT OF THE SUMMARY OF THE RESULTS OF THE CLINICAL TRIAL FOR LAYPERSONS
LABELLING OF INVESTIGATIONAL MEDICINAL PRODUCTS AND AUXILIARY MEDICINAL PRODUCTS